selinexor (KPT-330)

DRUG2 trials

Sponsors

Karyopharm Therapeutics Inc, Memorial Sloan Kettering Cancer Center

Conditions

Myelodysplastic SyndromesSquamous Cell Carcinoma

Phase 2

Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas

TerminatedNCT02213133

Karyopharm Therapeutics IncSquamous Cell Carcinoma

Start: 2014-09-22End: 2015-12-10Updated: 2023-01-26

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

CompletedNCT02228525

Memorial Sloan Kettering Cancer CenterMyelodysplastic Syndromes

Start: 2014-08-27End: 2021-04-06Updated: 2022-03-09

Related Papers

Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trial.

2020-08-0118 citations